annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 20E A new prognostic score in patients with malignant pleural mesothelioma.
(Abstract #7039)
G. Selvaggi, A. Billè, M. Gisabella, L. Righi, L. Errico, P. Borasio, F. Ardissone
Brd. 20F A retrospective analysis of second-line chemotherapy for malignant pleural
mesothelioma (MPM). (Abstract #7040)
N. M. La Verde, A. Bramati, M. Cinquini, M. Tiseo, E. Collovà, G. Michetti,
M. Lo Dico, A. Follador, M. C. Garassino, P. Zucali, on behalf of Orion Group
Brd. 20G Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant
pleural mesothelioma (MPM). (Abstract #7041)
E. Lorenzi, L. Gianoncelli, P. Zucali, G. Ceresoli, F. De Vincenzo, M. Simonelli,
C. Ripa, L. Giordano, A. Santoro
Brd. 20H Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial
using dasatinib in resectable malignant pleural mesothelioma.
(Abstract #7042)
A. S. Tsao, I. I. Wistuba, R. J. Mehran, J. Gil, M. Nunez, J. Lee, H. Lin,
S. M. Lippman, W. K. Hong
Brd. 21A A multimodality treatment for malignant pleural mesothelioma patients with
or without lymph node metastases. (Abstract #7043)
K. A. Cengel, A. Fernandes, R. Mick, D. Smith, M. Culligan, J. Stevenson,
D. Sterman, E. Glatstein, S. M. Hahn, J. S. Friedberg
Brd. 21B Phase II trial of consolidation chest radiotherapy for extensive-stage small
cell lung cancer. (Abstract #7044)
D. Yee, C. A. Butts, Q. S. Chu, D. W. Fenton, A. Joy, T. J. Reiman, M. Smylie,
W. Roa
Brd. 21C Pretreatment positron emission tomography (PET) scan standardized uptake
value (SUV) as a prognostic variable for overall survival in limited-stage
small cell lung cancer (L-SCLC). (Abstract #7045)
D. R. Gomez, G. W. Gladish, X. Wei, P. Allen, J. D. Cox, M. O’Reilly,
J. J. Erasmus, F. V. Fossella, R. Komaki
Brd. 21D A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer
(SCLC). (Abstract #7046)
C. M. Rudin, M. R. Oliveira, E. B. Garon, P. Bonomi, D. R. Camidge, C. Nolan,
T. Busman, A. Krivoshik, R. Humerickhouse, L. Gandhi
Brd. 21E Should large cell neuroendocrine carcinoma of the lung (LNEC) be classified
and treated as a small cell lung cancer (SCLC) or with other large cell
carcinomas (OLC)? (Abstract #7047)
M. M. DeCamp, J. M. Varlotto, J. C. Flickinger, E. Schaefer, A. Recht
Brd. 21F Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated
dose (MTD) evaluation (phase I step) followed by a phase II step in patients
(pts) with small cell lung cancer-extensive disease (SCLC-ED). (Abstract
#7048)
O. A. Cornely, J. Wolf, K. M. Josten, T. Mueller, H. A. Duerk, W. Neumeister,
M. Sebastian, C. Simonelli, A. Capriati, M. Karthaus, for the SABA with DDP
Working Group
Brd. 21G Phase II study of irinotecan and carboplatin followed by maintenance
sunitinib in the first-line treatment of extensive-stage small cell lung cancer.
(Abstract #7049)
E. T. Lubiner, D. R. Spigel, F. A. Greco, M. S. Rubin, D. Shipley, D. S. Thompson,
J. F. Eakle, R. H. Brown, H. A. Burris III, J. D. Hainsworth
Brd. 21H Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as
first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung
neuroendocrine cancer (NEC). (Abstract #7050)
J. Heymach, B. S. Glisson, R. C. Doebele, C. Huang, D. R. Gandara,
S. Le Scouiller, M. A. Marotti, D. R. Camidge
209
SUNDAY